Is there evidence for the added value and correct use of manual and automatically switching multimemory hearing devices? A scoping review

<p><i>Objectives</i>: To review literature on the use of manual and automatically switching multimemory devices by hearing aid and CI recipients, and to investigate if recipients appreciate and adequately use the ability to switch between programmes in various listening environments. <i>Design</i>: Literature was searched using PubMed, Embase and ISI/Web of Science. Additional studies were identified by screening reference and citation lists, and by contacting experts. <i>Study sample</i>: The search yielded 1109 records that were screened on title and abstract. This resulted in the full-text assessment of 37 articles. <i>Results</i>: Sixteen articles reported on the use of multiple programmes for various listening environments, three articles reported on the use of an automatic switching mode. All studies reported on hearing aid recipients only, no study with CI recipients fulfilled the selection criteria. <i>Conclusions</i>: Despite the high number of manual and automatically switching multimemory devices sold each year, there are remarkably few studies about the use of multiple programmes or automatic switching modes for various listening environments. No studies were found that examined the accuracy of the use of programmes for specific listening environments. An automatic switching device might be a solution if recipients are not able, or willing, to switch manually between programmes.</p

Human Salivary Micro-RNA in Patients with Parotid Salivary Gland Neoplasms

<div><p>Background</p><p>Currently, clinical examination, ultrasound scanning (with or without fine needle aspiration cytology), preoperative CT-scan and MRI are available for the differential diagnosis of parotid gland swelling. A preliminary non-invasive salivary diagnostic tool may be helpful in the clinical decision making process. Altered salivary micro-RNA (miRNA) expression levels have been observed in saliva from patients with various cancers. Therefore, we investigated miRNA expression levels in saliva samples from patients with a parotid gland neoplasm using Human miRNA cards in comparison to controls.</p><p>Results</p><p>In the discovery phase, eight miRNAs were identified having different expression levels in patients compared to controls. In the validation phase, the differences in miRNA expression levels between patients and controls were confirmed for seven out of eight discovered miRNAs (p < 0.001). A combination of two miRNAs yielded a receiver-operator-characteristics curve with an AUC of 0.94 (95% CI: 0.87–1.00; sensitivity 91%; specificity 86%). Validation of discovered miRNAs in segregated collected parotid saliva revealed that expression of these miRNAs differ between whole saliva and parotid saliva.</p><p>Conclusions</p><p>A two miRNA combination can predict the presence of a parotid gland neoplasm. Furthermore, this study suggested that the identified, patient-specific, salivary miRNAs were not derived from the parotid gland itself.</p></div

Box-and-whisker plot of the validation of miRNA expression in whole saliva samples.

<p>Samples were collected from patients with a parotid gland neoplasm (n = 46) and controls (n = 14). Whiskers represent maximum and minimum ΔCt values. * p < 0. 001.</p

Overview of the research design and saliva samples used in the discovery and validation phase.

<p>Overview of the research design and saliva samples used in the discovery and validation phase.</p

Patients’ characteristics.

<p>Patients’ characteristics of neoplasm samples and control samples used in the discovery and the validation phases.</p

Mean ΔCt (sd) and Wilcoxon 2-sided p-values of validated salivary miRNA biomarkers.

<p>The independent validation sample set consisted of whole saliva samples from patients with a parotid gland neoplasm (n = 46) and whole saliva samples from healthy controls (n = 14).</p

Detection of Distant Metastases in Head and Neck Cancer: Changing Landscape

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-018-0662-8"><b>here</b>.</a> </p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> • Audio slide

Nomogram for tube feeding dependence to determine normal tissue complication probability (NTCP) values for each individual patient.

<p>Abbreviations: SF, conventional radiotherapy; ART, accelerated radiotherapy; CRT, chemoradiation.</p

Pre-treatment charactistics in the training cohort and test cohort.

<p>Abbreviations: 3D-CRT, Three Dimensional Conformal Radiotherapy; IMRT, Intensity-Modulated Radiation Therapy; RTOG, Radiation Therapy Oncology Group.</p

Results of the LASSO analysis with tube feeding dependence at 6 months (TUBE_M6) as primary endpoint.

<p>Abbreviations: OR, Odds Ratio; CI, Confidence Interval; B, model coefficient beta.</p